XRCC1 is thus an endogenous PARP1 anti-trapper that safeguards genome integrity during BER by preventing PARP1 from impeding this essential DNA repair process in a manner reminiscent of anti-cancer PARP inhibitors. The gene discussed is XRCC1; the disease is cancer.